Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

1. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood advances · 2021
   Guideline
2. Qualitative analysis of out-of-hospital self-management capabilities and ongoing care needs in patients with gynecological malignancies and venous thromboembolism.Annals of medicine · 2026
   Article
3. Mitigating acute chemotherapy-associated adverse events in patients with cancer.Nature reviews. Clinical oncology · 2022
   Review
4. New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism.Drug design, development and therapy · 2022
   Review
5. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021
   Article
6. Nanotherapeutics for multiple myeloma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018
   Review
7. The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.Clinical & experimental metastasis · 2018
   Review
8. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.Internal and emergency medicine · 2015
   Article

Corrections and comments

• Comment on
  A prospective study on survival in cancer patients with and without venous thromboembolism.2014

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as